Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
Protheroe
Andrew
A
Cancer Research UK, Department of Medical Oncology, Churchill Hospital, Oxford. Kay.Castle@cancer.org.uk
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology*; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D043823:Taxoids; D000077143:Docetaxel; D008942:Mitoxantrone; D011241:Prednisone